Interview with Richard de Souza, CEO, Martindale Pharma
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Address: Hubert Road
Brentwood
Essex CM14 4JY
,United Kingdom
Tel: +44 (0) 1277 266 600
Web: http://www.martindalepharma.co.uk/
After starting out as a London chemist store owned by William Martindale, Martindale Pharma has remained in business for more than a century. The company’s reputation as a leading UK manufacturer and supplier of specialty prescription pharmaceutical products for healthcare professionals, working in both Primary and Secondary Care, has grown steadily over that time. Martindale Pharma is now firmly established as a leading supplier to the UK’s NHS and exports its products to a number of other major pharmaceutical markets. Martindale Pharma has a clearly defined mission: to provide medicines to improve the quality of people’s lives.
Martindale Pharma has built strong relationships with prescribers and influencers on drug choice in its chosen business segments (see below). Working on the basis of a partnership, Martindale Pharma has also built a strong relationship with healthcare service providers such as Alliance Boots, Celesio, AAH, Lloyds, Co-Operative Pharmacies, as well as the NHS. Our operating philosophy is one of close co-operation and responsiveness to customer needs.
Key Business Segments:
Addiction
Martindale Pharma is ranked number one in market share in the opiate addiction market, driven by the success of our brand Physeptone, the UK’s leading methadone product. We work in partnership with the NHS, Community Drug Teams, third party providers of addiction services as well as retail pharmacies to ensure that drug service users receive the optimum support as they seek to move away from the use of illicit opiates.
Critical Care
Martindale Pharma manufacture and market the Aurum Range, the UK’s leading range of 11 pre-filled syringes for emergency use by resuscitation and operating theatre teams. We also manufacture and market a Caffeine product for treatment of Apnoea of Prematurity a critical care area in neonatology.
Specials
Martindale Pharma can manufacture over 30,000 products in a range of formulations. Handling around 700-800 individual orders a day for these highly personalised medicines, the majority of products are made by our dedicated team of pharmacists and technical staff. Over 90% of orders are supplied to the customer within 24 hours of ordering. Martindale Pharma is ranked number one by market share in this segment.
Ophthalmics
Martindale Pharma provides a broad range of ophthalmic products as generic, own label and third party brands. We are one of the top three companies in our chosen Ophthalmics disease segments.
Hospital Speciality Products
Martindale Pharma’s range of principally parenteral products are used in a wide range of hospital situations. We are one of the country’s leading manufacturers of sterile injection products supplying over 25 million ampoules a year.
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease.…
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed…
Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James…
Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse…
With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland,…
After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR…
See our Cookie Privacy Policy Here